Όλο το DSpace

Πλοήγηση ανά Θέμα "tenofovir"

Αποτελέσματα 1-11 από 11

    • Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: Report from a high level conference 

      Papatheodoridis G., Thomas H.C., Golna C., Bernardi M., Carballo M., Cornberg M., Dalekos G., Degertekin B., Dourakis S., Flisiak R., Goldberg D., Gore C., Goulis I., Hadziyannis S., Kalamitsis G., Kanavos P., Kautz A., Koskinas I., Leite B.R., Malliori M., Manolakopoulos S., Matičič M., Papaevangelou V., Pirona A., Prati D., Raptopoulou-Gigi M., Reic T., Robaeys G., Schatz E., Souliotis K., Tountas Y., Wiktor S., Wilson D., Yfantopoulos J., Hatzakis A. (2016)
      Summary In the WHO-EURO region, around 28 million people are currently living with chronic viral hepatitis, and 120 000 people die every year because of it. Lack of awareness and understanding combined with the social ...

    • Daring-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B 

      Papatheodoridis G.V., Rigopoulou E.I., Papatheodoridi M., Zachou K., Xourafas V., Gatselis N., Hadziyannis E., Vlachogiannakos J., Manolakopoulos S., Dalekos G.N. (2018)
      Background: The remission rates after stopping antivirals in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) vary among studies, while reliable predictors of relapse have not been identified. This prospective ...

    • Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 

      Papatheodoridis G.V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Loglio A., Siakavellas S., Gatselis N., Keskın O., Lehretz M., Savvidou S., de la Revilla J., Hansen B.E., Kourikou A., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2018)
      Background & Aims: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival ...

    • Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Sypsa V., Dalekos G.N., Yurdaydin C., Van Boemmel F., Buti M., Calleja J.L., Chi H., Goulis J., Manolakopoulos S., Loglio A., Voulgaris T., Gatselis N., Keskin O., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Idilman R., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the ...

    • Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort 

      Papatheodoridis, G. V.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G. N. (2015)
      Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. ...

    • Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? 

      Tillmann, H. L.; Zachou, K.; Dalekos, G. N. (2012)
      Despite a decline in cases of acute hepatitis B and the low hepatitis B virus (HBV) chronicity rates in adults, still some patients progress to HBV-related fulminant liver failure. In this review, we discuss treatment ...

    • PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy 

      Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Mangia G., Gatselis N., Keskin O., Savvidou S., De La Revilla J., Hansen B.E., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2016)
      Background & Aims Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort study aimed to develop ...

    • Pulmonary infection by Rhodococcus equi presenting with positive Ziehl-Neelsen stain in a patient with human immunodeficiency virus: A case report 

      Spiliopoulou, A.; Assimakopoulos, S. F.; Foka, A.; Kolonitsiou, F.; Lagadinou, M.; Petinaki, E.; Anastassiou, E. D.; Spiliopoulou, I.; Marangos, M. (2014)
      Introduction: Patients with human immunodeficiency virus carry a significant risk of contracting opportunistic infections. The worldwide increased incidence of tuberculosis has instituted pulmonary tuberculosis as an ...

    • The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B 

      Papatheodoridis G.V., Idilman R., Dalekos G.N., Buti M., Chi H., van Boemmel F., Calleja J.L., Sypsa V., Goulis J., Manolakopoulos S., Loglio A., Siakavellas S., Keskın O., Gatselis N., Hansen B.E., Lehretz M., de la Revilla J., Savvidou S., Kourikou A., Vlachogiannakos I., Galanis K., Yurdaydin C., Berg T., Colombo M., Esteban R., Janssen H.L.A., Lampertico P. (2017)
      Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence ...

    • Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Dalekos G.N., Idilman R., Sypsa V., Van Boemmel F., Buti M., Calleja J.L., Goulis J., Manolakopoulos S., Loglio A., Papatheodoridi M., Gatselis N., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Yurdaydin C., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than ...

    • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

      Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
      The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...